Association between serum lithium level and incidence of COVID-19 infection - Archive ouverte HAL
Article Dans Une Revue British Journal of Psychiatry Année : 2022

Association between serum lithium level and incidence of COVID-19 infection

Association entre les niveau de lithium et l'incidence de l'infection à la Covid-19

Résumé

An antiviral effect of lithium has been proposed, but never investigated for COVID-19. Using electronic health records of 26,554 patients with documented serum lithium levels during the pandemic, we show that the 6-month COVID-19 infection incidence was lower among matched patients with 'therapeutic' (0.50-1.00) vs. 'sub-therapeutic' (0.05-0.50) lithium levels (HR 0.82, 95% CI 0.69-0.97, p=0.017) and among matched patients with 'therapeutic' lithium levels vs. patients using valproate (HR 0.79, 95% CI 0.67-0.92, p=0.0023). Lower rates of infection were observed for both new COVID-19 diagnoses and positive PCR tests, regardless of underlying psychiatric diagnosis and vaccination status.
Fichier principal
Vignette du fichier
Lithium_COVID_Submitted.pdf (170.39 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03623879 , version 1 (29-03-2022)

Identifiants

Citer

Livia de Picker, Marion Leboyer, John Geddes, Manuel Morrens, Paul Harrison, et al.. Association between serum lithium level and incidence of COVID-19 infection. British Journal of Psychiatry, 2022, ⟨10.1192/bjp.2022.42⟩. ⟨hal-03623879⟩

Collections

INSERM IMRB UPEC
168 Consultations
188 Téléchargements

Altmetric

Partager

More